Consistency Analysis of Gene Mutation Sites of Bone Marrow Tumor DNA and Circulating Tumor DNA in Patients with Myelodysplastic Syndrome.
10.7534/j.issn.1009-2137.2019.01.024
- Author:
Pan ZHAO
1
;
Qian-Ze ZHU
1
;
Teng FAN
1
;
Wei-Yi LIU
2
;
Hai-Yan XIAO
2
;
Jia-Yue QIN
3
;
Gang HUANG
4
;
Xiao-Mei HU
5
Author Information
1. Department of Hematology, Xiyuan Hospital, Academy of Chinese Medical Sciences, Beijing, 100091, China.Graduate School, Academy of Chinese Medical Sciences, Beijing, 100700, China.
2. Department of Hematology, Xiyuan Hospital, Academy of Chinese Medical Sciences, Beijing, 100091, China.
3. Annoroad Gene Technology Co. Ltd, Beijing 100176, China.
4. Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA.E-mail: Gang.Huang@cchmc.org.
5. Department of Hematology, Xiyuan Hospital, Academy of Chinese Medical Sciences, Beijing, 100091, China.E-mail: huxiaomei_2@163.com.
- Publication Type:Journal Article
- MeSH:
Bone Marrow Neoplasms;
Circulating Tumor DNA;
DNA, Neoplasm;
Humans;
Mutation;
Myelodysplastic Syndromes
- From:
Journal of Experimental Hematology
2019;27(1):149-158
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the consistency of gene mutation sites between bone marrow DNA (BM-tDNA) and perepheral plasma circulating tumor DNA (PP-ctDNA) in patients with myelodysplastic syndrome (MDS).
METHODS:The simultaneous sampled BM and PP from 19 patients (SBPP) was detected by NGS-127 gene panel, and the consistency of VAF between BM-tDNA and PP-ctDNA was analyzed. The peripheral blood cell tumor DNA (PC-tDNA) of 5 out of 19 patients was detected randomly, the consistency of VAF among PC-tDNA，BM-tDNA and PP-ctDNA was analyzed. The non simultaneous sampled BM and PP from 13 patients (NBPP) was detected, and the difference value of VAF between BM-tDNA and PP-ctDNA in SBPP and NBPP was analyzed.
RESULTS:The average concentration of PP-ctDNA in SBPP was 0.59 ng/µl and 0.604 ng/µl in NBPP. The median concentration of PP-ctDNA in SBPP and NBPP was 0.330 ng/µl and 0.338 ng/µl, respectively. The study showed a good consistency of VAF between BM-tDNA and PP-ctDNA in the SBPP (R=0.9693, P<0.05), and the consistency of VAF between BM-tDNA and PP-ctDNA in single base replacement (SNP) sites (R=0.9712) was better than that in insertion deletion (Indel) sites (R=0.6813). The results showed a good consistency of VAF between BM-tDNA and PP-ctDNA both in 12 patients before treatment (R=0.9325, P<0.05) and 5 patients (R=0.9875, P<0.05) after treatment. The results also showed that the VAF of PC-tDNA had a good consistency with the VAF of BM-tDNA (R=0.8783) and PP-ctDNA (R=0.8783) (P<0.05). The difference value of VAF between BM-tDNA and PP-ctDNA in SBPP was significantly lower than that in NBPP (P<0.05).
CONCLUSION:PP can replace BM as a biological sample for genes mutation detection in patients with MDS due to its stable concentration, high degree of consistency with bone marrow in clinical significant mutation sites and easy collection.
